Using Short Peptides to Retrain the Immune System and Treat Allergies

What the researchers found

T cell epitope peptide therapy — using carefully selected short peptide fragments from major allergens — has shown encouraging results in randomized, double-blind, placebo-controlled clinical trials. The peptides are designed to bind a wide range of immune system MHC class II molecules, allowing them to induce tolerance across genetically diverse patient populations.

Trials in cat allergy, house dust mite allergy, and grass pollen allergy have demonstrated significant efficacy with short treatment courses. The preferred delivery method is intradermal injection into non-inflamed skin, and adverse events have been inconsequential and non-systemic — a major safety advantage over traditional whole-allergen immunotherapy.

Why it matters

Traditional allergy immunotherapy requires years of regular injections with whole allergen extracts and carries a risk of severe allergic reactions. Peptide-based therapy could offer shorter treatment courses with better safety, since the peptide fragments are too small to trigger the IgE-mediated reactions that cause anaphylaxis. If successful, this approach could transform how hundreds of millions of allergy sufferers are treated.

How the study worked

This was a review of the field covering the progression from in vitro studies showing peptide-induced T cell anergy, through proof-of-concept mouse models, to current human clinical trials. The authors examined randomized, double-blind, placebo-controlled trials using mixtures of short allergen peptides or long contiguous overlapping peptides delivered intradermally.

What this study cannot tell us

The exact immunological mechanisms driving tolerance are not fully resolved — T cell anergy, Th2 deletion, immune deviation, and regulatory T cell induction are all implicated but their relative contributions are unclear. The review was published in 2016, and some of the clinical programs discussed may have since advanced or been discontinued. Long-term durability of the tolerance effect needs more data.

How to read the evidence

This review covers randomized, double-blind, placebo-controlled clinical trials, which is the gold standard for treatment evidence. However, as a narrative review rather than a systematic review, the evidence synthesis is selective rather than exhaustive.

When this study was published

Published in 2016, this review captures an important moment in peptide allergy therapy development. Some of the SPIRE programs have since progressed through clinical trials, making this a useful historical reference for understanding the field's trajectory.

The bigger picture

This sits within the broader movement toward precision immunotherapy — using the body's own immune recognition systems to correct disease rather than suppress symptoms. Peptide-based allergy treatment represents a convergence of peptide science and immunology, using the same MHC-peptide presentation system that drives cancer vaccines but redirecting it to induce tolerance rather than immune activation.

Questions still open

• How long does the tolerance induced by peptide immunotherapy last after treatment stops?
• Can this approach be extended to food allergies like peanut, where treatment reactions are a major safety concern?
• Will SPIRE-type products achieve regulatory approval and reach clinical practice?

Common questions

Read the original research

T Cell Epitope Peptide Therapy for Allergic Diseases.

Current allergy and asthma reports, 16(2), 14

Citation

O'Hehir, Robyn E; Prickett, Sara R; Rolland, Jennifer M. (2016). T Cell Epitope Peptide Therapy for Allergic Diseases.. Current allergy and asthma reports, 16(2), 14. https://doi.org/10.1007/s11882-015-0587-0